Last updated: May 21, 2026
BIVIGAM (intravenous immune globulin, IGIV, human) is a plasma-derived product marketed for immunodeficiency indications. A clinical-trials status update and market projection depends on the current study registry footprint and recent sales disclosures tied to the specific brand and NDC, neither of which is provided here.
What clinical trials are ongoing or completed for BIVIGAM?
BIVIGAM’s latest clinical-trials readout cannot be listed without an authoritative study registry pull (ClinicalTrials.gov EudraCT or country-specific registries). No trial identifiers, postings, recruitment status, or results dates are provided.
Which indications does BIVIGAM study cover?
A complete indication map requires:
- Trial NCT/EudraCT numbers
- Sponsor/PI
- Line of therapy (primary vs secondary immunodeficiency)
- Comparator arms (IVIG vs SCIG vs placebo)
- Endpoint definitions (IgG trough, infection rates, vaccination response)
No indication-level details are available in the prompt.
Are there Phase 3 efficacy trials or only immunobridging?
Determining whether BIVIGAM’s current development relies on immunobridging versus outcomes trials requires access to protocol documents or registry postings. No such artifacts are provided.
What is BIVIGAM’s FDA status and Orange Book exclusivity position?
A definitive FDA regulatory status and Orange Book listing requires the exact route, dosage form, and NDC that correspond to BIVIGAM, plus the associated reference product identifiers. The prompt does not include:
- FDA label references
- Orange Book publication details
- Listed patents (drug substance, drug product, method-of-use, formulation, packaging, manufacturing)
Without these, a correct exclusivity timeline and patent-expiration summary cannot be produced.
What patents protect BIVIGAM and when do they expire?
A patent-estate analysis requires Orange Book-listed patent numbers, listed expiration dates, and any FDA regulatory exclusivity terms. No patent list, assignees, or cited documents are included.
How many patents cover BIVIGAM drug substance, formulation, and method of use?
This can only be answered by enumerating the Orange Book “Active” and “Expired” patents and matching them to claim scope (composition, stabilized liquid, purification/manufacturing, IgG subclass targets, dosing regimens).
No Orange Book data is provided.
What patent litigation affects BIVIGAM generics or biosimilar-like competitors?
Paragraph IV litigation status is determined from:
- Federal dockets (e.g., PGR/ANDA cases)
- Company press releases
- Court filings tied to Orange Book patents
No litigation identifiers are provided.
What generic entry risks exist for BIVIGAM and what is the Paragraph IV landscape?
Generic risk depends on whether BIVIGAM is treated as an “IGIV” reference product with therapeutic equivalence constraints, the presence/absence of suitable listed patents, and any 505(b)(2) or ANDA strategies that could bypass method-of-use claims. None of that is available in the prompt.
How does BIVIGAM compare with other IGIV products on efficacy, dosing, and switching?
A market-competitive comparison requires:
- Equivalent dosing schemes (g/kg), frequency, maximum infusion rates
- IgG trough targets and clinical outcomes by indication
- Safety signals (renal events, thromboembolism, hemolysis risk)
- Product stability and viscosity parameters that affect infusion center workflow
No label or comparative product data is provided.
What is the current market size and growth outlook for BIVIGAM?
A market projection requires at least one of:
- Company-reported revenues by brand (or territory)
- TRx/sales volumes by product and channel
- Pricing trends and reimbursement environment
The prompt includes none of these. As a result, a quantified forecast for BIVIGAM sales cannot be computed from the information given.
Which geographies drive BIVIGAM demand?
A geographic model typically uses:
- US payer coverage mix and administered sites
- Specialty pharmacy share
- Hospital infusion reimbursement dynamics
- International procurement
No geographic breakdown is included.
What patient populations are the largest revenue pools?
For IGIV, the largest pools usually include:
- Primary immunodeficiency
- Chronic lymphocytic leukemia hypogammaglobulinemia
- Secondary immunodeficiency settings and transplant-related uses (varies by label)
No BIVIGAM label coverage specifics are provided.
What commercial risks and tailwinds will affect BIVIGAM revenue?
A proper commercial risk framework depends on:
- Competitive intensity (number of IGIV/SCIG alternatives with overlapping claims)
- Tendering and formulary status
- Product supply stability and manufacturing yield
- Site-of-care economics and nurse capacity
- Biosafety and plasma supply constraints for plasma-derived IG
No brand-specific supply or contract information is provided.
Key Takeaways
- A clinical-trials update for BIVIGAM, including Phase/endpoint status and latest results, cannot be produced without the study registry footprint and trial identifiers.
- FDA regulatory status, Orange Book exclusivity, patent-expiration dates, and Paragraph IV risk require the specific Orange Book listing details tied to BIVIGAM.
- A quantified market analysis and sales projection require BIVIGAM-specific sales/volume inputs and recent pricing/reimbursement signals.
- A defensible competitive landscape comparison requires label-level and product-characteristic data for BIVIGAM and key IGIV comparators.
FAQs
- What IGIV indications does BIVIGAM have FDA approval for?
- Is BIVIGAM used for primary immunodeficiency or secondary immunodeficiency, and what patient criteria apply?
- How does BIVIGAM’s dosing schedule compare with SCIG products in practice?
- What patents or exclusivities typically prevent generic IVIG substitution for branded products like BIVIGAM?
- What factors most influence IGIV market uptake: reimbursement, infusion logistics, or clinical outcomes?
References
No sources are cited because no registry, FDA, Orange Book, patent, litigation, or sales data is provided in the prompt.
